Wolwo Bio‑Pharma Surges with Phase I TB Drug Approval: Market Outlook
Explore Zhejiang Wolwo’s breakthrough: Phase I approval for its first‑in‑class TB drug S01D, promising new growth and investor potential.
- ZHEJIANG WOLWO BIO-PHARMAC
- China
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read
